Glaxo’s Earnings Beat Estimates as New Product Sales DoubleBy
Profit was 24.5 pence a share; analysts expected 21 pence
Weaker British pound helps Glaxo earn more from U.S. sales
GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, reported second-quarter earnings that beat analysts’ estimates and raised its forecast for the year as sales of new products doubled.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.